Cost and Healthcare Utilization of Methicillin-resistant Bacteremia Estimated from Linked Antimicrobial Resistance Surveillance and Hospital Claims Data in Japan

Overview

Journal Antimicrob Steward Healthc Epidemiol

Publisher Cambridge University Press

Specialty Infectious Diseases

Date 2022 Dec 9

PMID 36483379

Authors

Tomokazu Shoji

Ryusei Muto

Haruhisa Fukuda

Yuichi Muraki

Keishi Kawata

Manabu Akazawa

Affiliations

Soon will be listed here.

Abstract

Objective: To compare the incremental costs and healthcare utilization of methicillin-resistant (MRSA) bacteremia with those of methicillin-susceptible (MSSA) bacteremia.

Design: Retrospective cohort study using data from April 2014 to March 2015.

Setting: Antimicrobial resistance surveillance and hospital claims data from 16 Japanese hospitals.

Patients: The study included 73 patients with bacteremia: 23 with MRSA and 50 with MSSA.

Methods: MRSA bacteremia was identified using blood cultures and drug-susceptibility tests. MRSA- and MSSA-related medical practices were evaluated. The costs were calculated and compared. All the medical costs were classified into empirical and definitive therapy periods and expressed in Japanese yen (JPY, 1 USD = 106 JPY). Additionally, costs at aggressive and passive bacterial test-performing facilities were compared.

Results: No significant differences existed in MRSA-related resource use per patient episode between MRSA and MSSA bacteremia during empirical therapy. However, during definitive therapy, in MRSA bacteremia compared with MSSA bacteremia, this difference was higher. The average MRSA-related costs of empirical therapy for MRSA and MSSA were 13,380 and 9,140 JPY (126 and 86 USD) per patient, and for definitive therapy, they were 69,810 and 29,510 JPY (659 and 278 USD) per patient, respectively. No significant differences were noted. Conversely, the average examination costs during definitive therapy differed significantly: 9,740 vs 3,850 JPY (92 vs 36 USD), respectively ( .0294). Furthermore, the incremental costs in aggressive facilities were lower for the definitive therapy period than those in passive facilities.

Conclusions: In the definitive therapy period, MRSA bacteremia had higher incremental costs and greater use of healthcare resources. In addition, the incremental costs in aggressive facilities were lower than those in passive facilities.

Citing Articles

Estimated medical costs of methicillin-resistant infection classified by polymerase chain reaction-based open reading frame typing in Japan.

Shoji T, Muto R, Sakai R, Matsumura H, Uchida T, Kitta F AIMS Microbiol. 2023; 8(4):528-543.

PMID: 36694583 PMC: 9834076. DOI: 10.3934/microbiol.2022034.

References

Cosgrove S, Sakoulas G, Perencevich E, Schwaber M, Karchmer A, Carmeli Y . Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2002; 36(1):53-9. DOI: 10.1086/345476. View

Rubio-Terres C, Garau J, Grau S, Martinez-Martinez L . Cost of bacteraemia caused by methicillin-resistant vs. methicillin-susceptible Staphylococcus aureus in Spain: a retrospective cohort study. Clin Microbiol Infect. 2009; 16(6):722-8. DOI: 10.1111/j.1469-0691.2009.02902.x. View

McDanel J, Perencevich E, Diekema D, Herwaldt L, Smith T, Chrischilles E . Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals. Clin Infect Dis. 2015; 61(3):361-7. DOI: 10.1093/cid/civ308. View

Mimura W, Fukuda H, Akazawa M . Antimicrobial utilization and antimicrobial resistance in patients with haematological malignancies in Japan: a multi-centre cross-sectional study. Ann Clin Microbiol Antimicrob. 2020; 19(1):7. PMC: 7027235. DOI: 10.1186/s12941-020-00348-0. View

Seigel T, Cocchi M, Salciccioli J, Shapiro N, Howell M, Tang A . Inadequacy of temperature and white blood cell count in predicting bacteremia in patients with suspected infection. J Emerg Med. 2010; 42(3):254-9. DOI: 10.1016/j.jemermed.2010.05.038. View

Blot S, Vandewoude K, Hoste E, Colardyn F . Outcome and attributable mortality in critically Ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med. 2002; 162(19):2229-35. DOI: 10.1001/archinte.162.19.2229. View

Cosgrove S, Qi Y, Kaye K, Harbarth S, Karchmer A, Carmeli Y . The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol. 2005; 26(2):166-74. DOI: 10.1086/502522. View

Landrum M, Neumann C, Cook C, Chukwuma U, Ellis M, Hospenthal D . Epidemiology of Staphylococcus aureus blood and skin and soft tissue infections in the US military health system, 2005-2010. JAMA. 2012; 308(1):50-9. DOI: 10.1001/jama.2012.7139. View

El Atrouni W, Knoll B, Lahr B, Eckel-Passow J, Sia I, Baddour L . Temporal trends in the incidence of Staphylococcus aureus bacteremia in Olmsted County, Minnesota, 1998 to 2005: a population-based study. Clin Infect Dis. 2009; 49(12):e130-8. PMC: 3050712. DOI: 10.1086/648442. View

10.

Kimmig A, Hagel S, Weis S, Bahrs C, Loffler B, Pletz M . Management of Bloodstream Infections. Front Med (Lausanne). 2021; 7:616524. PMC: 7973019. DOI: 10.3389/fmed.2020.616524. View

11.

Coburn B, Morris A, Tomlinson G, Detsky A . Does this adult patient with suspected bacteremia require blood cultures?. JAMA. 2012; 308(5):502-11. DOI: 10.1001/jama.2012.8262. View

12.

Strich J, Heil E, Masur H . Considerations for Empiric Antimicrobial Therapy in Sepsis and Septic Shock in an Era of Antimicrobial Resistance. J Infect Dis. 2020; 222(Suppl 2):S119-S131. PMC: 7372215. DOI: 10.1093/infdis/jiaa221. View

13.

Uematsu H, Yamashita K, Kunisawa S, Fushimi K, Imanaka Y . Estimating the disease burden of methicillin-resistant Staphylococcus aureus in Japan: Retrospective database study of Japanese hospitals. PLoS One. 2017; 12(6):e0179767. PMC: 5487039. DOI: 10.1371/journal.pone.0179767. View

14.

de Kraker M, Davey P, Grundmann H . Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med. 2011; 8(10):e1001104. PMC: 3191157. DOI: 10.1371/journal.pmed.1001104. View

15.

You J, Choi K, Wong T, Ip M, Ming W, Wong R . Disease Burden, Characteristics, and Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection in Hong Kong. Asia Pac J Public Health. 2017; 29(5):451-461. DOI: 10.1177/1010539517717365. View

16.

Uematsu H, Yamashita K, Kunisawa S, Fushimi K, Imanaka Y . The economic burden of methicillin-resistant Staphylococcus aureus in community-onset pneumonia inpatients. Am J Infect Control. 2016; 44(12):1628-1633. DOI: 10.1016/j.ajic.2016.05.008. View

17.

Tsuzuki S, Matsunaga N, Yahara K, Gu Y, Hayakawa K, Hirabayashi A . National trend of blood-stream infection attributable deaths caused by Staphylococcus aureus and Escherichia coli in Japan. J Infect Chemother. 2019; 26(4):367-371. DOI: 10.1016/j.jiac.2019.10.017. View

18.

Goto M, Schweizer M, Vaughan-Sarrazin M, Perencevich E, Livorsi D, Diekema D . Association of Evidence-Based Care Processes With Mortality in Staphylococcus aureus Bacteremia at Veterans Health Administration Hospitals, 2003-2014. JAMA Intern Med. 2017; 177(10):1489-1497. PMC: 5710211. DOI: 10.1001/jamainternmed.2017.3958. View

19.

Uematsu H, Yamashita K, Mizuno S, Kunisawa S, Shibayama K, Imanaka Y . Effect of methicillin-resistant Staphylococcus aureus in Japan. Am J Infect Control. 2018; 46(10):1142-1147. DOI: 10.1016/j.ajic.2018.04.214. View

20.

Shoji T, Sato N, Fukuda H, Muraki Y, Kawata K, Akazawa M . Clinical Implication of the Relationship between Antimicrobial Resistance and Infection Control Activities in Japanese Hospitals: A Principal Component Analysis-Based Cluster Analysis. Antibiotics (Basel). 2022; 11(2). PMC: 8868447. DOI: 10.3390/antibiotics11020229. View